AR087508A1 - 3,4-dihidro-1h-[1,8]naftiridinonas antibacterianas sustituidas con ciclopenta[c]pirrol - Google Patents

3,4-dihidro-1h-[1,8]naftiridinonas antibacterianas sustituidas con ciclopenta[c]pirrol

Info

Publication number
AR087508A1
AR087508A1 ARP120102929A ARP120102929A AR087508A1 AR 087508 A1 AR087508 A1 AR 087508A1 AR P120102929 A ARP120102929 A AR P120102929A AR P120102929 A ARP120102929 A AR P120102929A AR 087508 A1 AR087508 A1 AR 087508A1
Authority
AR
Argentina
Prior art keywords
benzyl
alkyl
halo
heteroaryl
hydrogen
Prior art date
Application number
ARP120102929A
Other languages
English (en)
Spanish (es)
Original Assignee
Janssen R & D Ireland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46650549&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR087508(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen R & D Ireland filed Critical Janssen R & D Ireland
Publication of AR087508A1 publication Critical patent/AR087508A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
ARP120102929A 2011-08-10 2012-08-10 3,4-dihidro-1h-[1,8]naftiridinonas antibacterianas sustituidas con ciclopenta[c]pirrol AR087508A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11177119 2011-08-10

Publications (1)

Publication Number Publication Date
AR087508A1 true AR087508A1 (es) 2014-03-26

Family

ID=46650549

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120102929A AR087508A1 (es) 2011-08-10 2012-08-10 3,4-dihidro-1h-[1,8]naftiridinonas antibacterianas sustituidas con ciclopenta[c]pirrol

Country Status (24)

Country Link
US (7) US8906923B2 (enExample)
EP (1) EP2742045B1 (enExample)
JP (2) JP5921687B2 (enExample)
KR (1) KR101996862B1 (enExample)
CN (2) CN105461684B (enExample)
AR (1) AR087508A1 (enExample)
AU (1) AU2012293621B2 (enExample)
BR (1) BR112014003063B1 (enExample)
CA (1) CA2842518C (enExample)
CL (1) CL2014000289A1 (enExample)
DK (1) DK2742045T3 (enExample)
EA (1) EA201490438A1 (enExample)
ES (1) ES2721658T3 (enExample)
HU (1) HUE042978T2 (enExample)
IL (1) IL230549A (enExample)
JO (1) JO3611B1 (enExample)
MX (1) MX348128B (enExample)
PE (1) PE20141410A1 (enExample)
PH (1) PH12014500317A1 (enExample)
TR (1) TR201905537T4 (enExample)
TW (1) TWI568731B (enExample)
UA (1) UA111210C2 (enExample)
UY (1) UY34253A (enExample)
WO (1) WO2013021054A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013021052A1 (en) 2011-08-10 2013-02-14 Janssen R&D Ireland Antibacterial piperidinyl substituted 3,4-dihydro-1h-[1,8]naphthyridinones
JO3611B1 (ar) * 2011-08-10 2020-08-27 Janssen Sciences Ireland Uc سايكلو بنتا (سي (بيرول 4,3 ثاني هيدرو 1 hمستبدله [8,1] نافثيريدينونات مضادة للجراثيم
WO2014023814A1 (en) * 2012-08-10 2014-02-13 Janssen R&D Ireland New antibacterial compounds
US9540324B2 (en) 2013-09-26 2017-01-10 Luc Therapeutics, Inc. Selective octahydro-cyclopenta[C] pyrrole negative modulators of NR2B
JO3579B1 (ar) * 2014-09-26 2020-07-05 Luc Therapeutics Inc مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول
AR111295A1 (es) 2017-03-20 2019-06-26 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr)
US11691967B2 (en) 2018-03-12 2023-07-04 The Board Of Trustees Of The University Of Illinois Antibiotics effective for gram-negative pathogens
WO2020061255A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activating pyruvate kinase r
US20200129485A1 (en) 2018-09-19 2020-04-30 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
LT3880675T (lt) 2018-11-12 2024-12-27 Debiopharm International Sa Antibiotikų junginiai, jų gamybos būdas, farmacinės kompozicijos, kurių sudėtyje jie yra, ir jų panaudojimas
MX2022003025A (es) 2019-09-19 2022-04-07 Forma Therapeutics Inc Activacion de la piruvato cinasa r.
MX2023010941A (es) * 2021-03-17 2023-11-28 Janssen Sciences Ireland Unlimited Co Compuestos antibacterianos.
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4215123A (en) * 1979-05-07 1980-07-29 American Home Products Corporation Antisecretory 4-oxy-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives
EP1225895B1 (en) 1999-10-08 2005-05-04 Affinium Pharmaceuticals, Inc. Fab i inhibitors
JP4831907B2 (ja) 1999-10-08 2011-12-07 アフィニアム・ファーマシューティカルズ・インコーポレイテッド FabI阻害剤
ES2231275T3 (es) 1999-10-08 2005-05-16 Affinium Pharmaceuticals, Inc. Inhibidores de fab i.
JP4387804B2 (ja) 2001-04-06 2009-12-24 アフィニアム・ファーマシューティカルズ・インコーポレイテッド FabI阻害剤
US8450307B2 (en) 2004-06-04 2013-05-28 Affinium Pharmaceuticals, Inc. Therapeutic agents, and methods of making and using the same
US7732612B2 (en) 2004-09-09 2010-06-08 Janssen Pharmaceutica, N.V. 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones
US7973060B2 (en) 2005-10-13 2011-07-05 Crystalgenomics, Inc. Fab I inhibitor and process for preparing same
EP2054422B1 (en) 2006-07-20 2017-06-14 Debiopharm International SA Acrylamide derivatives as fab i inhibitors
WO2008098374A1 (en) * 2007-02-16 2008-08-21 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab i inhibitors
CA2776849A1 (en) * 2009-11-18 2011-05-26 Fab Pharma S.A.S. Novel heterocyclic acrylamides and their use as pharmaceuticals
US8766017B2 (en) 2011-07-29 2014-07-01 Eastman Chemical Company Integrated process for the preparation of 1,4-cyclohexanedimethanol from terephthalic acid
CA2843643A1 (en) 2011-07-29 2013-02-07 The Children's Hospital Of Philadelphia Compositions and methods for the treatment of hiv
JO3611B1 (ar) * 2011-08-10 2020-08-27 Janssen Sciences Ireland Uc سايكلو بنتا (سي (بيرول 4,3 ثاني هيدرو 1 hمستبدله [8,1] نافثيريدينونات مضادة للجراثيم
CN104039782A (zh) 2011-08-10 2014-09-10 爱尔兰詹森研发公司 抗菌的高哌啶基取代的3,4二氢1h[1,8]萘啶酮类
WO2013021052A1 (en) 2011-08-10 2013-02-14 Janssen R&D Ireland Antibacterial piperidinyl substituted 3,4-dihydro-1h-[1,8]naphthyridinones

Also Published As

Publication number Publication date
MX348128B (es) 2017-05-26
HK1199243A1 (zh) 2015-06-26
UA111210C2 (uk) 2016-04-11
TWI568731B (zh) 2017-02-01
CA2842518A1 (en) 2013-02-14
US8906923B2 (en) 2014-12-09
US9884864B2 (en) 2018-02-06
US20150080413A1 (en) 2015-03-19
ES2721658T3 (es) 2019-08-02
CA2842518C (en) 2019-07-23
US20160194324A1 (en) 2016-07-07
JP2016190843A (ja) 2016-11-10
PH12014500317A1 (en) 2014-04-14
IL230549A0 (en) 2014-03-31
US9290493B2 (en) 2016-03-22
KR101996862B1 (ko) 2019-07-05
IL230549A (en) 2017-07-31
EP2742045B1 (en) 2019-01-23
US10155759B2 (en) 2018-12-18
CL2014000289A1 (es) 2014-07-11
CN105461684B (zh) 2018-09-25
CN103874698B (zh) 2016-03-23
UY34253A (es) 2013-02-28
JO3611B1 (ar) 2020-08-27
NZ620212A (en) 2015-10-30
KR20140072034A (ko) 2014-06-12
WO2013021054A1 (en) 2013-02-14
US20190084982A1 (en) 2019-03-21
TW201313714A (zh) 2013-04-01
BR112014003063B1 (pt) 2020-11-17
AU2012293621B2 (en) 2016-07-21
HUE042978T2 (hu) 2019-07-29
US10501463B2 (en) 2019-12-10
US9617262B2 (en) 2017-04-11
TR201905537T4 (tr) 2019-05-21
JP2014531404A (ja) 2014-11-27
MX2014001600A (es) 2014-04-25
HK1223352A1 (zh) 2017-07-28
US20140171451A1 (en) 2014-06-19
EA201490438A1 (ru) 2014-06-30
US10526331B2 (en) 2020-01-07
US20170174683A1 (en) 2017-06-22
BR112014003063A2 (pt) 2017-02-21
JP5921687B2 (ja) 2016-05-24
CN105461684A (zh) 2016-04-06
US20190194194A1 (en) 2019-06-27
US20180105525A1 (en) 2018-04-19
DK2742045T3 (en) 2019-04-23
EP2742045A1 (en) 2014-06-18
CN103874698A (zh) 2014-06-18
PE20141410A1 (es) 2014-10-13
AU2012293621A1 (en) 2014-02-13

Similar Documents

Publication Publication Date Title
ES2721658T3 (es) 3,4-dihidro-1h-[1,8]naftiridinonas sustituidas con ciclopenta[c]pirrol antibacterianas
ES2653265T3 (es) Morfinanos sustituidos y el uso de éstos
ECSP11011365A (es) Sales de adición de aminas que contienen grupos hidroxilo y/o carboxílicos con derivados de ácido aminonicotínico como inhibidores de dhodh
AR076435A1 (es) Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
PH12015501083B1 (en) Novel pyridine derivatives
MX2015007883A (es) Compuestos para protección de células.
MY153617A (en) Pyridin-4-yl derivatives
CA2875877C (en) Syk inhibitors
AR092790A1 (es) Derivados bencimidazolicos del acido hidroxamico
AR073598A1 (es) Pirrolidinas 2-carboxamidas sustituidas, composiciones farmaceuticas que las contienen y uso de las mismas como agentes anticancer.
CO6241157A2 (es) "derivados de 6-(pirrolidin-3-il)-1h-pirazolo{3,4-d}pirimidin-4(5h)-ona utiles como inhibidores de pde9"
AR094911A1 (es) SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO ASÍ COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARÍNICO M₃
AR087919A1 (es) Heterociclos biciclicos como inhibidores de irak4
AR091519A1 (es) Inhibidores pirrolopirazona de tanquirasa
MX343264B (es) Ciertas amino-piridazinas, composiciones de las mismas y metodos de uso de los mismos.
JO3261B1 (ar) مشتق بيريدين أحادي الحلقة
PH12015501843A1 (en) Novel pyrazol derivatives
AR091271A1 (es) Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa
PH12015501073A1 (en) Novel pyridine derivatives
NZ709986A (en) Pharmaceutical compositions comprising nitroxyl donors
AR066153A1 (es) Derivados de piperidina / piperazina
PH12015501933A1 (en) Novel pyridine derivatives
MY169179A (en) Novel piperidine compound or salt thereof
AR080596A1 (es) Compuestos alquilamido y composiciones farmaceuticas
ES2570167T3 (es) Derivados de benzimidazol como inhibidores de glutaminil ciclasa

Legal Events

Date Code Title Description
FG Grant, registration